

September 30th, 2021, 2 pm (Paris GMT+2)

ZOOM LINK>> (no registration required)

14h00	Opening lecture: Nongenetic mechanisms of drug tolerance and resistance in melanoma Jean-Christophe MARINE , VIB-KU Leuven, Belgium
14h40	Jean-Emmanuel SARRY , Cancer Research Center of Toulouse <i>Metabolic drivers of residual disease in acute myeloid leukemia</i>
15h05	Julie PANNEQUIN (IGF, Montpellier) <i>Role of translational control in the colorectal cancer cell plasticity in response to 5-FU</i>
15h25	Jill CORRE , IUCT Oncopole & Cancer Research Center of Toulouse <i>Minimal residual disease in multiple myeloma: pathogenic and clinical implications</i>
15h45	Marie-Julie NOKIN , European Institute of Chemistry and Biology & Inserm U1218, Bordeaux <i>Redox detoxification as a druggable vulnerability in drug-tolerant BRAF-mutant lung cancer</i>

16h00	eCoffee break
--------------	----------------------

16h15	Lecture: Metabolic vulnerabilities of leukemia stem cells Craig JORDAN , University of Colorado Anschutz Medical Campus, USA
16h50	Stanislas DU MANOIR , Montpellier Cancer Research Institute <i>Platinum-sensitive High Grade Ovarian Carcinoma post-treatment residual tumors undergo a drug-tolerant state and share joint expression of CRYAB, CEACAM6 and SOX2 genes with tumors that acquired resistance</i>
17h05	Cathy SAWAI , Inserm U1218, Bordeaux <i>A novel model to study the in vivo functions of normal hematopoietic and leukemic stem cells during chronic myeloid leukemia</i>
17h30	Closing lecture: Identification and molecular characterization of the earliest metastasis founder cells in melanoma Christoph KLEIN , Experimental Medicine and Therapy Research; University of Regensburg, Germany